Batjargal, Khishigjargal

Now showing 1 - 4 of 4

Some of the metrics are blocked by your
consent settings
High Prevalence of Preexisting Neutralizing Antibodies Against Adeno-Associated Virus Capsids in Mongolian People with Hemophilia
(2026-10)
Baatartsogt, Nemekhbayar
;
Batchuluun, Khongorzul
;
Kashiwakura, Yuji
;
Amarbayasgalan, Munkhuu
;
Nordog, Munkhuchral
Adeno-associated virus (AAV) vector-mediated gene therapy for hemophilia offers the potential for sustained therapeutic benefit after a single administration and is particularly attractive in regions with limited access to standard therapies. However, the prevalence of anti-AAV neutralizing antibodies (NAbs), which can impair therapeutic efficacy, varies geographically and remains poorly characterized in Mongolia. Here, we evaluated the seroprevalence of NAbs against clinically relevant AAV serotypes in Mongolia. NAbs against AAV3B, AAV5, and AAV8 were assessed in serum samples from 23 healthy volunteers and 52 people with hemophilia (PwH) using a validated cell-based transduction inhibition assay. A high seroprevalence of anti-AAV NAbs was observed across all three serotypes in both healthy volunteers (69.6%-87.0%) and PwH (78.9%-84.6%), with no significant differences between groups. NAbs were detected across all age groups, including early childhood, and frequently exhibited neutralization against multiple AAV serotypes, which was associated with higher NAb titers. Taken together, anti-AAV NAbs are highly prevalent and acquired early in life in the Mongolian population, with multiserotype neutralization patterns. These findings identify a substantial population-specific barrier to AAV-mediated gene therapy and highlight the need for alternative therapeutic strategies beyond AAV-based platforms to overcome immunological constraints in this setting.
Some of the metrics are blocked by your
consent settings
Newborn screening and biobanking for preventable genetic disorders in Mongolia: A developing country perspective
(Elsevier BV, 2026-12)
Batchuluun, Khongorzul
;
Batjargal, Khishigjargal
;
Tsevgee, Altantuya
;
Enkhtur, Altansuvd
;
Stipan, Nurbyek
Newborn screening (NBS) is an important public health program, yet its implementation is highly uneven globally, with developing countries like Mongolia facing significant resource and infrastructure limitations that hinder early detection of preventable genetic disorders. Meanwhile, induced pluripotent stem cell (iPSC) technology, leveraged through biobanking, offers a powerful platform for disease modeling, drug discovery, and regenerative medicine, though its advanced applications are primarily concentrated in wealthier nations. We review the current status of NBS in Mongolia and argue for linking an expanded NBS program to an iPSC biobank. This link would improve diagnosis, create a foundation for Mongolian precision medicine, and strengthen local research capacity. We recognize the practical and ethical hurdles-funding, staffing, and data governance-and outline phased rollout, targeted training, and international partnerships as realistic next steps. Taken together, this approach could prevent avoidable disability in Mongolia while gradually building homegrown capability in genetic healthcare.
Some of the metrics are blocked by your
consent settings
First Experiences with Newborn Screening for Congenital Hypothyroidism in Ulaanbaatar, Mongolia
(MDPI AG, 2021-06)
Tsevgee, Altantuya
;
Batjargal, Khishigjargal
;
Munkhchuluun, Tsolmon
;
Khurelbaatar, Naranchimeg
;
Nansal, Gerelmaa
Congenital hypothyroidism (CH) is among the most common conditions leading to intellectual disability, which can be prevented by early detection through newborn screening (NBS). In Mongolia, a regional screening program for CH was launched in 2000, which was supported by the International Atomic Energy Agency (IAEA) for the Asia Pacific Region. In our present study, a total of 23,002 newborns from nine districts in Ulaanbaatar were screened between 2012 and 2020, by the measurement of the thyroid-stimulating hormone (TSH) from dried blood spots, sampled 24 to 72 h after birth. The level of TSH was measured by the DELFIA assay. The overall CH prevalence confirmed at birth was 1/2091. The female-to-male ratio for CH cases was 1.8:1. The majority of patients were asymptomatic (72.7% of CH cases); umbilical hernia and cold or mottled skin were reported symptoms in patients with CH (27.3%). Thyroid dysgenesis (hypoplasia and agenesis) was the most common etiology, with a total of nine cases (81.8%) out of the eleven patients. The lapse between the birth date and the initiation of L-thyroxine treatment in CH-positive children was lower than 15 days in 63.64% of cases or 15 to 30 days in 36.36% of children. Further research is required to expand the screening coverage for CH in Mongolia.
Scopus© Citations 5
Some of the metrics are blocked by your
consent settings
Functional analysis of PAX8 variants identified in patients with congenital hypothyroidism in situ.
(2022)
Batjargal, Khishigjargal
;
Tajima, Toshihiro
;
Fujita-Jimbo, Eriko
;
Yamaguchi, Takeshi
;
Nakamura, Akie
Scopus© Citations 3

Batjargal, Khishigjargal

Filters

Settings

Sort By

Results per page